Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| ATC prefix |
|
| ATC suffix |
|
| CAS number |
|
| DrugBank |
|
| FDA UNII code |
|
| is product of |